Adam Colborn, JD

At AMCP 2026, Adam Colborn, JD, warns the Alternatives to PAIN Act may expand access but risk destabilizing Medicare Part D and limiting plan participation.

Adam Colburn, JD, highlights 3 federal bills to expand value-based care, digital therapeutics, and pharmacist reimbursement across Medicare and Medicaid.

Adam Colborn, JD, associate vice president of congressional affairs at AMCP, shares insights on the impact of the Most Favored Nation drug pricing order when it comes to access, affordability, and innovations in US health care.

Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy (AMCP), shares updates on the Ensuring Community Access to Pharmacist Services (ECAPS) Act of 2025, which was introduced in the House of Representatives last month.

Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy, highlights key policy updates that are impacting managed care pharmacy.

Attendees of the Academy of Managed Care Pharmacy annual meeting share explain what draws them to the conference year after year.

Adam Colborn, JD, associate vice president for congressional affairs, AMCP, discusses key regulatory factors that managed care professionals must consider when implementing artificial intelligence (AI) in practice.

Abandoning efforts to reform payment for cell and gene therapies for Medicaid beneficiaries could allow ongoing access barriers to persist, said Adam Colborn, JD, of AMCP.

Adam Colborn, JD, of AMCP, discusses the complexities of drug pricing and what policymakers must consider in efforts to reduce prices and increase access.

Adam Colborn, JD, of AMCP, discussed how President Trump's rescission of several Biden-era executive orders may impact Medicaid and Medicare initiatives.